SLC34A1

Chr 5

solute carrier family 34 member 1

Also known as: FRTS2, HCINF2, NAPI-3, NPHLOP1, NPT2, NPTIIa, SLC11, SLC17A2

Enables sodium:phosphate symporter activity. Involved in several processes, including phosphate ion homeostasis; response to cadmium ion; and response to lead ion. Located in several cellular components, including apical plasma membrane; mitotic spindle; and nuclear speck. Implicated in several diseases, including Fanconi syndrome (multiple); chronic kidney disease; hereditary hypophosphatemic rickets with hypercalciuria; hypophosphatemic nephrolithiasis/osteoporosis 1; and nephrolithiasis. [provided by Alliance of Genome Resources, Jul 2025]

ResearchGenerating clinical summary…
MultiplemechanismLOEUF 1.83
Clinical SummarySLC34A1
🧬
Gene-Disease Validity (ClinGen)
hypercalcemia, infantile, 2 · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

2 total gene-disease associations curated

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
59 unique Pathogenic / Likely Pathogenic· 282 VUS of 581 total submissions
Some data sources returned errors (1)

omim: Error: OMIM fetch failed: 429

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
1.83LOEUF
pLI 0.000
Z-score -1.85
OE 1.41 (1.071.83)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?
-0.48Z-score
OE missense 1.07 (0.981.16)
400 obs / 374.1 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?
LoF OE?1.41 (1.071.83)
00.351.4
Missense OE?1.07 (0.981.16)
00.61.4
Synonymous OE?1.02
01.21.6
LoF obs/exp: 34 / 24.2Missense obs/exp: 400 / 374.1Syn Z: -0.24

This gene — mechanism propensity

DN
0.76top 25%
GOF
0.73top 25%
LOF
0.3746th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative and gain-of-function). Both the Badonyi & Marsh prediction and the broader genomic evidence point to dominant-negative as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median · 1 literature citation
GOFprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

DNThese results indicate that the mutant proteins altered the function of the wild-type NPT2a through a dominant negative effect.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

References

  1. 1.PMID 12324554

ClinVar Variant Classifications

581 submitted variants in ClinVar

Classification Summary

Pathogenic25
Likely Pathogenic34
VUS282
Likely Benign174
Benign23
Conflicting40
25
Pathogenic
34
Likely Pathogenic
282
VUS
174
Likely Benign
23
Benign
40
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
19
4
2
0
25
Likely Pathogenic
27
7
0
0
34
VUS
9
239
28
6
282
Likely Benign
0
7
66
101
174
Benign
0
1
19
3
23
Conflicting
40
Total55258115110578

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

58 pathogenic / likely-pathogenic (of 70) ClinVar copy-number / structural variants overlap SLC34A1 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

SLC34A1 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →